Despite EPS growth outpacing share price increases, the market is cautious towards the stock. Zhejiang Jingxin Pharmaceutical's 17% return is near the market's -17% return. If fundamentals stay strong, the share price drop could be an investment opportunity.

Zhejiang Jingxin Pharmaceutical's strong financials, higher than average ROE, decent net income growth, and efficient reinvestment of earnings could potentially boost its stock value. Analysts expect earnings to gain momentum.

Investors anticipate limited future growth, justifying the company's low P/E ratio. Insufficient potential for earnings improvement may keep the share price at current levels.

Zhejiang Jingxin Pharmaceutical's financial performance remains strong with above-average ROE and successful reinvestment of profits. The company's promising earnings growth track is expected to continue.